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R985For decades detailed molecular 
biology about malaria has been 
accrued: but, throughout this 
time, the most effective measures 
in regions where the disease is 
endemic have continued to rely 
on the chemical and physical 
methods of insecticides and 
bednets, with drugs available to 
people travelling to these regions. 
So the latest study to test a new 
malaria vaccine developed by 
GlaxoSmithKline (GSK) in African 
infants has raised hopes that 
at last, this body of knowledge 
is being harnessed for the 
development of new treatments. 
The results of this latest study, 
published in The Lancet, suggest 
that, in this key group of the 
population, the vaccine has a 
Safety tests suggest a new 
malaria vaccine is tolerated by 
very young babies most at risk 
from the disease, and provides 
some protection too, encouraging 
further trials. Nigel Williams 
reports.
Malaria vaccine 
boostpromising safety and tolerance 
profile and reduces parasite 
infection and chronic illness due 
to malaria.
The primary objective of this 
study was to assess whether the 
vaccine — called RTS,S — could 
be safely administered to young 
infants most vulnerable to severe 
disease and death from malaria. 
For the study, 214 infants between 
10 and 18 weeks of age were 
enrolled in clinics in Mozambique, 
where the disease is prevalent. 
The vaccine’s safety and response 
was similar to those observed with 
the vaccines for other diseases 
already routinely administered to 
these infants.
The study reports that vaccine 
efficacy against new infections 
was 65 per cent over a three-
month follow-up period after the 
infants received all three doses 
of the vaccine. The results also 
showed that the vaccine reduced 
episodes of clinical malaria by  
35 per cent over a six-month 
follow-up period starting after  
the final dose.
The vaccine uses a recombinant 
protein that comprises part 
of the malaria parasite’s 
circumsporozoite protein — one of the first parasite proteins to 
be exposed to the host’s immune 
system — combined with a 
hepatitis B surface antigen and 
an adjuvant system created by 
researchers at GSK.
The efficacy data are consistent 
with the results from a previous 
Mozambique trial in 2004 in 
children one to four years old.
The trial was conducted by the 
Manhica Health Research Centre 
in Mozambique by researchers 
from the University of Barcelona 
and the Mozambique ministry of 
health. It was supported by the 
PATH malaria vaccine initiative —  
an international not-for-profit 
organization — which is a key 
partner in the clinical development 
of RTS,S. It provided funding  
for the trial based on a grant 
from the Bill & Melinda Gates 
Foundation.
“This study paves the way 
for a pivotal Phase III trial of 
what could be the first malaria 
vaccine for infants and young 
children in Africa,” said Christian 
Loucq, director of the PATH 
malaria vaccine initiative. “The 
world urgently needs a safe and 
effective vaccine to reduce the 
suffering malaria causes.”Barrier: A new vaccine may help provide more protection from malaria-carrying mosquitoes. (Photo: © Scott Camazine/Alamy.)
